StockWatch
·

Alamar Biosciences, Inc. Q2 FY26 Results

ALMRQ2 FY26 Results
Filing
MetricValue ($ M)Q1 FY26Q2 FY25
Revenue29.4313.0%82.1%
Total Income29.4313.0%82.1%
Expenditure42.9611.9%78.4%
PBT-13.2936.3%89.3%
Net Profit-13.2038.1%88.0%
OPM-45.98%1.44pp3.01pp
NPM-44.85%37.06pp1.40pp
EPS-0.2287.4%64.5%
View full financials

Alamar Biosciences Reports Q2 2026 Financial Results and Provides 2026 Revenue Guidance

11 Aug 2026 · 11 Aug, 1:45 am

Summary

Alamar Biosciences reported strong second quarter 2026 financial results, with total revenue reaching $29.4 million, an 82% increase year-over-year. This growth was driven by significant increases in both consumable revenue (up 147%) and instrument revenue (up 35%). The company also saw an improvement in gross margin to 60% from 53% in the prior year period. Management provided full-year 2026 revenue guidance between $116 million and $120 million, projecting 59% growth at the midpoint.

Key Highlights

  1. 1

    Alamar Biosciences generated $29.4 million of total revenue for the second quarter of 2026, an increase of 82% as compared to the corresponding period of 2025.

  2. 2

    Consumable revenue grew 147% to $15.5 million, from $6.3 million for the corresponding prior-year period, driven primarily by strong demand for multiplex panels.

  3. 3

    Instrument revenue grew 35% to $7.8 million, from $5.8 million for the corresponding prior-year period, driven primarily by continued growth in new instrument placements.

  4. 4

    Gross margin was 60% for the second quarter of 2026, as compared to 53% for the corresponding prior-year period, driven by manufacturing efficiencies and a favorable shift in mix toward high-margin consumables.

  5. 5

    The company launched the first commercial multiplexed blood-based immunoassay for eMTBR-tau, available in their NULISAseq™ Neuro 220 Panel and through their Technology Access Program.

  6. 6

    Alamar Biosciences is providing full-year 2026 revenue guidance of $116 million to $120 million, representing growth of 59% at the midpoint of the range as compared to 2025.

Management Comments

Y

Yuling Luo

We delivered a strong second quarter with consumable revenue growing nearly 150% year-over-year. With the recent launches of eMTBR-tau and the Immune 340 Panel strengthening our content menu and extending into new disease areas, we believe we are well-positioned to sustain momentum into the coming quarters.

Informational and educational content only. Not investment advice.